Like Laiya Consulting, Inc.

closed 9/2/2020 via Company Press Release

Cytel Inc., acquired Laiya Consulting, Inc.

synopsis: Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. Laiya pioneered the delivery of trial design software using SaaS, which aligns with Cytel’s goal of making all of its design software available as a cloud-based service.
buyer parent: New Mountain Capital, LLC
buyer: Cytel Inc.
Cytel provides statistical software for clinical trials. Cytel provides an understanding of software tools that solve statistical problems and that meet the highest standards of reliability, technical documentation and customer support. "
target: Laiya Consulting, Inc.
Founded in 2010, Laiya Consulting has supported drug developers to drive success rates and maximize portfolio returns through the design and implementation of Bayesian adaptive trials, robust clinical strategies, and integrated software platforms.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/26/2012 via BusinessWire

Accenture, acquired Octagon Research Solutions, Inc.

synopsis: Accenture completed its acquisition of Octagon Research Solutions, a provider of clinical and regulatory information management solutions and software for the pharmaceutical industry. The acquisition enhances Accenture's existing clinical services capabilities – including clinical data management, clinical programming and safety case processing.
buyer: Accenture (ACN:$44,327.04)
Accenture is a global management consulting, technology services and outsourcing company. Accenture collaborates with clients to help them become high performance businesses and governments. "
target parent: Edison Ventures
target: Octagon Research Solutions, Inc.
Octagon Research Solutions is the world leader in clinical and regulatory information management solutions to the life sciences industry. Through an integrated suite of outsourced services, strategic consulting, and innovative technology, Octagon optimizes the entire drug development lifecycle.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/20/2019 via BNC Analysis

Monterro, acquired Viedoc

synopsis: Monterro, the leading B2B software investor in the Nordics, has acquired a majority stake in Viedoc, a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently.
buyer: Monterro
Sweden-based Monterro is the leading B2B software investor in the Nordics, with a mission to turn software companies into market leaders. With operational experience from successfully developing and running companies, Monterro actively supports its portfolio companies in all aspects of growth. "
target: Viedoc
Viedoc is a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently. Their powerful EDC system has been used in over 2000 trials in more than 75 countries in all therapeutic areas and clinical phases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2019 via BNC Analysis

TrialScope, acquired Clinical Trial Connect, LLC

synopsis: TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
target: Clinical Trial Connect, LLC
Clinical Trial Connect is a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. Clinical Trial Connect was founded by Mike Wenger, who developed his own algorithm for matching patients to clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/28/2019 via BNC Analysis

JLL Partners, Water Street Healthcare Partners, acquired THREAD Research

synopsis: Water Street Healthcare Partners and JLL Partners have acquired Orange County, California-based THREAD, a provider of technology that enables virtual research approaches to modernize clinical studies and registries.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
JLL Partners is a middle-market private equity firm with a 30-year track record of building and transforming businesses. Water Street is a strategic investor focused exclusively on healthcare. The firm has a strong record of building market-leading companies across key growth sectors in healthcare. "
target: THREAD Research
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
target: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$5,061.43)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 4/10/2019 via BNC Analysis

TriNetX, acquired Custodix N.V.

synopsis: TriNetX has acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions. TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance.
buyer: TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and CROs to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. "
target: Custodix N.V.
Custodix is a Belgian provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/6/2019 via PE Hub

Catalyst Clinical Research, LLC, acquired Tri Stat

synopsis: Catalyst Clinical Research, LLC, a leading provider of clinical operation solutions to the biotechnology, pharmaceutical and medical device companies, has acquired Triangle Biostatistics, LLC (Tri Stat), a leading provider of statistical programming, statistical consulting, and data management services for the pharmaceutical industry.
buyer parent: NovaQuest
buyer: Catalyst Clinical Research, LLC
Catalyst Clinical Research is a leading provider of clinical operation solutions to the biotechnology, pharmaceutical and medical device companies. The company assists clients with their clinical development programs by providing therapeutically-aligned experts and teams and customized solutions. "
target: Tri Stat
Triangle Biostatistics (Tri Stat) is a leading provider of statistical programming, statistical consulting, and data management services for the pharmaceutical industry. Tri Stat provides strong statistical consulting and programming support utilizing the latest computing technology.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/6/2019 via Company Press Release

Advarra, acquired Kinetiq

synopsis: Advarra, the premier provider of institutional review board (IRB) and research quality and compliance consulting services, acquired Quorum’s research and technology consulting division, Kinetiq. Kinetiq delivers innovative solutions for human subject protection and compliance in clinical research.
buyer parent: Linden Capital Partners
buyer: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. "
target parent: Quorum Review IRB
target: Kinetiq
Kinetiq is a consulting and technology division of Quorum Review IRB that delivers innovative solutions for human subject protection and compliance in clinical research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/17/2018 via Company Press Release

Oracle Corporation, will acquire GoBalto

synopsis: Oracle announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is a computer technology corporation developing and marketing computer hardware systems and enterprise software products. By eliminating complexity and simplifying IT, Oracle enables its customers to accelerate innovation and create added value for their customers. "
target: GoBalto
goBalto, Inc. is an award winning, venture backed group of industry veterans that creates simple, focused software for the global drug trial industry. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2018 via BusinessWire

Anju Software, acquired Sylogent

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent. Sylogent delivers cloud based state of the art software solutions and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
target: Sylogent
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. They ensure the timely completion of critical information, maximize compliance goals and reduce risk management liability.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/16/2016 via BNC Analysis

DrugDev, acquired SecureConsent

synopsis: DrugDev has acquired SecureConsent, a developer of mobile e-consent software. SecureConsent replaces the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
buyer: DrugDev
DrugDev streamlines engagement among sponsors, CROs and doctors to advance the common goal of doing more trials. Through the creation of global, standardized processes DrugDev is consistently and efficiently transforming the way drug developers identify, engage and pay investigators. "
target: SecureConsent
The software products developed by Secure Consent replace the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2016 via PR Newswire

BioClinica, Inc., acquired Clinverse, Inc.

synopsis: Bioclinica, Inc., a specialty trials services and technology provider, announced it has acquired Clinverse, Inc. Clinverse automates and manages the entire financial lifecycle of global clinical trials for contract research organizations and pharmaceutical companies. Its suite of products pays clinical trial sites, vendors and their subjects.
buyer: BioClinica, Inc.
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized into three business segments to deliver focused service and multifaceted technologies. "
target: Clinverse, Inc.
Clinverse, Inc. architected the industry's first automated financial management technology solution for clinical trials. Their solution standardizes clinical trial financial management for millions of financial transactions across the globe, including clinical site payments.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/17/2015 via PR Web

Aris Global LLC, acquired Medsight Solutions Inc.

synopsis: ArisGlobal®, a leading provider of Cloud solutions to life sciences companies, is pleased to announce that it has acquired Medsight Solutions, including the revolutionary integrated risk management solution, Medsight Sapphire (now known as ArisGlobal agBalance™).
buyer: Aris Global LLC
For more than 20 years, ArisGlobal has led in the development of innovative software solutions for pharmacovigilance & safety, regulatory affairs, clinical research and medical information. "
target: Medsight Solutions Inc.
Medsight Solutions Inc. is a life sciences solutions and professional services company with specialties in Clinical trial optimization, Benefit-risk assessment and Compliance monitoring.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/3/2014 via PR Newswire

PAREXEL International Corporation, acquired ClinIntel Ltd.

synopsis: PAREXEL International Corporation, a global clinical research organization, announced that the Company has acquired all of the outstanding equity securities of privately-owned ClinIntel, a provider of clinical Randomization and Trial Supply Management (RTSM) services, based in the United Kingdom.
buyer: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. "
target: ClinIntel Ltd.
Headquartered in the United Kingdom, ClinIntel is a provider of clinical Randomization and Trial Supply Management (RTSM) services. The company was founded in 2009, and works with biopharmaceutical companies and contract research organizations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/24/2014 via PR Newswire

The WIRB-Copernicus Group, acquired ePharmaSolutions, Inc.

synopsis: WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced that ePharmaSolutions (ePS) has joined its group of companies. ePharmaSolutions is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of regulatory and ethical solutions for clinical research, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review. "
target: ePharmaSolutions, Inc.
ePharmaSolutions is a leading provider of eClinical solutions and specialty clinical services that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/16/2014 via PR Newswire

BioClinica, Inc., acquired Blueprint Clinical

synopsis: BioClinica®, Inc., a leading provider of eClinical Solutions for the Pharmaceutical Industry, has announced the acquisition of Blueprint Clinical, a fast-growing company offering ground-breaking technology and extensive expertise to drive successful Risk-Based Monitoring (RBM) strategies for clinical trials.
buyer parent: JLL Partners
buyer: BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated clinical trial management technologies including eClinical solutions for clinical trial supply management, forecasting and optimization, electronic data capture, randomization, and clinical trial management. "
target: Blueprint Clinical
Blueprint Clinical, Inc. creates Software-as-a-Service tools that help improve monitoring of clinical trials. Their first product, Blueprint Clinical Compass™, ultimately allows risk based monitoring implementation thereby improving quality and efficiency of clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/27/2013 via Company Press Release

PPD, Inc., acquired Acurian, Inc.

synopsis: Pharmaceutical Product Development, LLC, a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services, announced it has acquired Acurian, a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Acurian, Inc.
Acurian, Inc. provides solutions needed to recruit, enroll, and retain patients for clinical trials. It offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions; and formulates a plan based on historical performance data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2020 via Company Press Release

Cytel Inc., acquired Laiya Consulting, Inc.

synopsis: Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. Laiya pioneered the delivery of trial design software using SaaS, which aligns with Cytel’s goal of making all of its design software available as a cloud-based service.
buyer parent: New Mountain Capital, LLC
buyer: Cytel Inc.
Cytel provides statistical software for clinical trials. Cytel provides an understanding of software tools that solve statistical problems and that meet the highest standards of reliability, technical documentation and customer support. "
target: Laiya Consulting, Inc.
Founded in 2010, Laiya Consulting has supported drug developers to drive success rates and maximize portfolio returns through the design and implementation of Bayesian adaptive trials, robust clinical strategies, and integrated software platforms.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2020 via Company Press Release

Cytel Inc., acquired Laiya Consulting, Inc.

synopsis: Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. Laiya pioneered the delivery of trial design software using SaaS, which aligns with Cytel’s goal of making all of its design software available as a cloud-based service.
buyer parent: New Mountain Capital, LLC
buyer: Cytel Inc.
Cytel provides statistical software for clinical trials. Cytel provides an understanding of software tools that solve statistical problems and that meet the highest standards of reliability, technical documentation and customer support. "
target: Laiya Consulting, Inc.
Founded in 2010, Laiya Consulting has supported drug developers to drive success rates and maximize portfolio returns through the design and implementation of Bayesian adaptive trials, robust clinical strategies, and integrated software platforms.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2020 via Company Press Release

Cytel Inc., acquired Laiya Consulting, Inc.

synopsis: Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. Laiya pioneered the delivery of trial design software using SaaS, which aligns with Cytel’s goal of making all of its design software available as a cloud-based service.
buyer parent: New Mountain Capital, LLC
buyer: Cytel Inc.
Cytel provides statistical software for clinical trials. Cytel provides an understanding of software tools that solve statistical problems and that meet the highest standards of reliability, technical documentation and customer support. "
target: Laiya Consulting, Inc.
Founded in 2010, Laiya Consulting has supported drug developers to drive success rates and maximize portfolio returns through the design and implementation of Bayesian adaptive trials, robust clinical strategies, and integrated software platforms.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/27/2013 via PR Newswire

Temis Text Intelligence, acquired i3 Analytics

synopsis: TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, announced that they have acquired the US-based i3 Analytics. i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data.
buyer: Temis Text Intelligence
In order to develop and market innovative Text Mining Solutions, TEMIS was founded in September 2000 by a team of managers, researchers and consultants from IBM. This skilled team had earlier developed and distributed IBM Text Mining solutions worldwide "
target: i3 Analytics
i3 Analytics is a provider of advanced data analytics and visualization technologies. Their Biopharma Navigator is an analytics tool that allow users to map clinical trials landscapes, scan the horizon for the latest news, and stay current on what researchers are doing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/23/2020 via BusinessWire

Curi Bio, acquired Dana Solutions

synopsis: Curi Bio has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
buyer: Curi Bio
Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. "
target: Dana Solutions
Dana Solutions is a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/28/2020 via BusinessWire

Recursion Pharmaceuticals, Inc., acquired Vium, Inc.

synopsis: Recursion, a digital biology™ company leading in the industrialization of drug discovery, has announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research.
buyer: Recursion Pharmaceuticals, Inc.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, AI, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. "
target: Vium, Inc.
Vium is the first company to create a fully digital end to end Digital Vivarium® platform which is transforming in vivo research. The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/13/2018 via BusinessWire

Certara, acquired Pirana Software

synopsis: Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence solutions, announced that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
buyer parent: Arsenal Capital Partners
buyer: Certara
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. "
target: Pirana Software
Pirana is a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/20/2019 via BNC Analysis

Monterro, acquired Viedoc

synopsis: Monterro, the leading B2B software investor in the Nordics, has acquired a majority stake in Viedoc, a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently.
buyer: Monterro
Sweden-based Monterro is the leading B2B software investor in the Nordics, with a mission to turn software companies into market leaders. With operational experience from successfully developing and running companies, Monterro actively supports its portfolio companies in all aspects of growth. "
target: Viedoc
Viedoc is a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently. Their powerful EDC system has been used in over 2000 trials in more than 75 countries in all therapeutic areas and clinical phases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2019 via BNC Analysis

TrialScope, acquired Clinical Trial Connect, LLC

synopsis: TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
target: Clinical Trial Connect, LLC
Clinical Trial Connect is a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. Clinical Trial Connect was founded by Mike Wenger, who developed his own algorithm for matching patients to clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/28/2019 via BNC Analysis

JLL Partners, Water Street Healthcare Partners, acquired THREAD Research

synopsis: Water Street Healthcare Partners and JLL Partners have acquired Orange County, California-based THREAD, a provider of technology that enables virtual research approaches to modernize clinical studies and registries.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
JLL Partners is a middle-market private equity firm with a 30-year track record of building and transforming businesses. Water Street is a strategic investor focused exclusively on healthcare. The firm has a strong record of building market-leading companies across key growth sectors in healthcare. "
target: THREAD Research
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
target: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$5,061.43)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 4/10/2019 via BNC Analysis

TriNetX, acquired Custodix N.V.

synopsis: TriNetX has acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions. TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance.
buyer: TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and CROs to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. "
target: Custodix N.V.
Custodix is a Belgian provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/17/2018 via Company Press Release

Oracle Corporation, will acquire GoBalto

synopsis: Oracle announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is a computer technology corporation developing and marketing computer hardware systems and enterprise software products. By eliminating complexity and simplifying IT, Oracle enables its customers to accelerate innovation and create added value for their customers. "
target: GoBalto
goBalto, Inc. is an award winning, venture backed group of industry veterans that creates simple, focused software for the global drug trial industry. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2018 via BusinessWire

Anju Software, acquired Sylogent

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent. Sylogent delivers cloud based state of the art software solutions and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
target: Sylogent
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. They ensure the timely completion of critical information, maximize compliance goals and reduce risk management liability.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/16/2016 via BNC Analysis

DrugDev, acquired SecureConsent

synopsis: DrugDev has acquired SecureConsent, a developer of mobile e-consent software. SecureConsent replaces the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
buyer: DrugDev
DrugDev streamlines engagement among sponsors, CROs and doctors to advance the common goal of doing more trials. Through the creation of global, standardized processes DrugDev is consistently and efficiently transforming the way drug developers identify, engage and pay investigators. "
target: SecureConsent
The software products developed by Secure Consent replace the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2016 via PR Newswire

BioClinica, Inc., acquired Clinverse, Inc.

synopsis: Bioclinica, Inc., a specialty trials services and technology provider, announced it has acquired Clinverse, Inc. Clinverse automates and manages the entire financial lifecycle of global clinical trials for contract research organizations and pharmaceutical companies. Its suite of products pays clinical trial sites, vendors and their subjects.
buyer: BioClinica, Inc.
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized into three business segments to deliver focused service and multifaceted technologies. "
target: Clinverse, Inc.
Clinverse, Inc. architected the industry's first automated financial management technology solution for clinical trials. Their solution standardizes clinical trial financial management for millions of financial transactions across the globe, including clinical site payments.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/17/2015 via PR Web

Aris Global LLC, acquired Medsight Solutions Inc.

synopsis: ArisGlobal®, a leading provider of Cloud solutions to life sciences companies, is pleased to announce that it has acquired Medsight Solutions, including the revolutionary integrated risk management solution, Medsight Sapphire (now known as ArisGlobal agBalance™).
buyer: Aris Global LLC
For more than 20 years, ArisGlobal has led in the development of innovative software solutions for pharmacovigilance & safety, regulatory affairs, clinical research and medical information. "
target: Medsight Solutions Inc.
Medsight Solutions Inc. is a life sciences solutions and professional services company with specialties in Clinical trial optimization, Benefit-risk assessment and Compliance monitoring.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 2/27/2015 via PR Newswire

ERT, will acquire PHT Corporation

synopsis: ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, and PHT Corporation, the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research, announced that they have signed a definitive agreement under which ERT will acquire PHT.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data. "
target parent: Boston Millennia Partners
target: PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/3/2014 via PR Newswire

PAREXEL International Corporation, acquired ClinIntel Ltd.

synopsis: PAREXEL International Corporation, a global clinical research organization, announced that the Company has acquired all of the outstanding equity securities of privately-owned ClinIntel, a provider of clinical Randomization and Trial Supply Management (RTSM) services, based in the United Kingdom.
buyer: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. "
target: ClinIntel Ltd.
Headquartered in the United Kingdom, ClinIntel is a provider of clinical Randomization and Trial Supply Management (RTSM) services. The company was founded in 2009, and works with biopharmaceutical companies and contract research organizations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/24/2014 via PR Newswire

The WIRB-Copernicus Group, acquired ePharmaSolutions, Inc.

synopsis: WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced that ePharmaSolutions (ePS) has joined its group of companies. ePharmaSolutions is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of regulatory and ethical solutions for clinical research, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review. "
target: ePharmaSolutions, Inc.
ePharmaSolutions is a leading provider of eClinical solutions and specialty clinical services that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Laiya Consulting, Inc.


read more

Laiya Consulting, Inc.

Octagon Research Solutions, Inc.

Viedoc

Clinical Trial Connect, LLC

THREAD Research

OmniComm Systems, Inc.

Medidata

Custodix N.V.

Tri Stat

Kinetiq

GoBalto

Sylogent

Parallel 6

SecureConsent

Clinverse, Inc.

Medsight Solutions Inc.

ClinIntel Ltd.

ePharmaSolutions, Inc.

Blueprint Clinical

Acurian, Inc.

read more

Laiya Consulting, Inc.

read more

Laiya Consulting, Inc.

read more

Laiya Consulting, Inc.

i3 Analytics

Dana Solutions

Vium, Inc.

Pirana Software

Viedoc

Clinical Trial Connect, LLC

THREAD Research

OmniComm Systems, Inc.

Medidata

Custodix N.V.

GoBalto

Sylogent

Parallel 6

SecureConsent

Clinverse, Inc.

Medsight Solutions Inc.

PHT Corporation

ClinIntel Ltd.

ePharmaSolutions, Inc.

Geography
Matching Companies
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2019
rev ($mm)
$30.83
EBITDA ($mm)
$4.12
EBIT ($mm)
$3.15
Net Income ($mm)
$2.27
Employees
238
  • drill down
  • watch
Ticker: SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc.
Scrypt, Inc.
Since 1998, Austin-based Scrypt, Inc. has been creating elegant document productivity tools for healthcare that eliminate manual processes and paper to save time and money. Scrypt has more than 30,000 customers across all 50 states.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.85)
EBIT ($mm)
($0.91)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: OM:RTC
 
 
 
 
 
 
 
 
Rethinking Care AB
Rethinking Care AB
Rethinking Care introduces a holistic concept in nursing & health, based on 3 interacting spheres of activity - "Software as a service", "Care as a service" & "Health as a service", based on a high level of competence in nursing & healthcare services as well as IT tools developed for health care.
year
2016
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: INOV
 
 
 
 
 
 
 
 
Inovalon, Inc.
Inovalon, Inc.
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape.
year
2017
rev ($mm)
$449.36
EBITDA ($mm)
$75.91
EBIT ($mm)
$27.16
Net Income ($mm)
$34.82
Employees
2119
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch